Genome Center for Alzheimer's Disease

 

Alzheimer's disease (AD) affects 3-5 million people costing the US over $100 billion dollars/year. By 2050, there will be 16 million people with AD costing the US $1 trillion dollars/year. There is no way to prevent AD, and current therapies are marginally effective and do not halt disease progression. More fundamental knowledge on disease mechanism is needed and will come in part from findings by ADSP and GCAD.

The Genome Center for Alzheimer's Disease (GCAD) is funded under the NIA cooperative agreement/specialized center award U54 AG052427 to identify genetic variants that cause, influence risk, or protect against this disorder, and to identify the underlying genes affected by these variants. The dbGaP ADSP study page is available at phs000572.

 

Mission

 
The role of the Genome Center for Alzheimer’s Disease (GCAD) is to coordinate the integration and meta-analysis of all available Alzheimer’s disease (AD) relevant genetic data with the goal of identifying AD risk/causative/protective genetic variants and eventual therapeutic targets.
 
 
To this end, GCAD will:
  • Harmonize all AD-relevant genetic data and phenotype data to be compatible for use in subsequent analysis. This will include sequence data generated by the Alzheimer’s Disease Sequence Project (ADSP) and data from other sources;
  • Analyze the Alzheimer’s Disease Sequence Project (ADSP) Follow-Up Phase data for AD risk/causative/protective genetic variants;
  • Provide a combined analysis of the ADSP Discovery and Follow-Up data for AD risk/causative/protective genetic variants; and
  • Extend the Replication analyses by meta-analyzing ADSP and non-ADSP genetics data for AD risk/causative/protective genetic variants.
 
As mandated by NIA, the GCAD will broadly disseminate all results and derivative data [e.g. imputed genotypes, variant call format (VCF) files recalled using ADSP protocols, etc.]. All GCAD results and derivative data will be distributed to ADSP and other AD investigators, particularly those working on functional analysis of AD-associated genetic variants.